Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 11.96M P/E - EPS this Y 47.40% Ern Qtrly Grth -
Income -19.12M Forward P/E - EPS next Y 92.60% 50D Avg Chg 3.00%
Sales 4.02M PEG - EPS past 5Y - 200D Avg Chg -10.00%
Dividend N/A Price/Book 0.40 EPS next 5Y - 52W High Chg -57.00%
Recommedations 1.50 Quick Ratio 3.10 Shares Outstanding 8.74M 52W Low Chg 15.00%
Insider Own - ROA -52.66% Shares Float 4.95B Beta 0.68
Inst Own 0.89% ROE -104.47% Shares Shorted/Prior 12.54K/22.96K Price 2.91
Gross Margin 94.67% Profit Margin - Avg. Volume 4,925 Target Price -
Oper. Margin -612.91% Earnings Date Aug 28 Volume 720 Change 0.69%
About Alterity Therapeutics Limited

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Alterity Therapeutics Limited News
11/19/24 Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary
11/12/24 Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
11/06/24 Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434
10/31/24 Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
10/14/24 Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
10/11/24 Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
10/02/24 Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
09/30/24 Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
09/23/24 Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
07/31/24 Appendix 4C – Q4 FY24 Quarterly Cash Flow Report
07/24/24 Alterity Therapeutics to Present at MST Financial Webinar
07/18/24 Alterity (ATHE) Up on Interim Data From Advance MSA Study
07/17/24 Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
06/12/24 Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
05/29/24 Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study
05/08/24 Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
04/30/24 Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
04/29/24 Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
04/17/24 Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
04/10/24 Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
ATHE Chatroom

User Image Stmkr Posted - 8 hours ago

$ATHE Jan 2025 ph2 RCT readout. Cash as of Sep 9.2M. Cash used per quarter 3.3M. Unless they do a surprise offering before the readout there should at least be a run-up towards the readout

User Image NEWBIGTECH Posted - 22 hours ago

$ATHE. Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary. Appointment of dual role CFO/Company Secretary streamlines corporate leadership New officer brings extensive financial and wealth management experience from major institutions Strong educational background and professional credentials (CFA)

User Image tlaw88999 Posted - 4 days ago

$ATHE dilution a little longer as expected/hang in there

User Image CARTE_BLANCHE_DEVEREAUX Posted - 1 week ago

@Winttard @Kloompa @ovk23 @GPS_21_vs_5_wBAT Might also want to look at $ATHE

User Image CARTE_BLANCHE_DEVEREAUX Posted - 1 week ago

$ATHE Slowly added 500 here and there over the last 6 months... today's 500 purchase puts me at 60k shares. I would say that I am well over my risk tolerance, but... the entire Market is outside my risk tolerance currently. Let's see that data!

User Image PatrickBateman69 Posted - 1 week ago

$ATHE The main question here is if they have enough cash for their pipeline and that we get some good news before they run out of cash. Hoping that they will not do a share dilution to raise capital before any significant news. Biotech is risky folks, but the levels that we are seeing is at an all time low. I can’t imagine that it would go below 1,0. We have seen it maintain over 1,20 from August to October which is great. Biotech is a risky play, but ATHE is really showing that it has been stabile compared with other Biotech companies.

User Image tlaw88999 Posted - 1 week ago

$ATHE

User Image JediGreen Posted - 1 week ago

$ATHE Pipeline - Alterity Therapeutics https://alteritytherapeutics.com/pipeline/

User Image Cub911 Posted - 1 week ago

$ATHE will be running very soon...load up..

User Image PatrickBateman69 Posted - 1 week ago

$ATHE Quite before the storm. ⛈️

User Image WiseGuyInvestin Posted - 1 week ago

$ATHE The big question is the financial aspect. The science is sound but how will they raise significant amounts of money to bring this to market in a shareholder friendly way?

User Image Cub911 Posted - 1 week ago

$ATHE need it to cross 52 weeks high which is 5.4

User Image Cub911 Posted - 1 week ago

$ATHE when is athe gonna run..😊

User Image JediGreen Posted - 1 week ago

$ATHE Thinking of adding another 4K in it at this price. Then I’ll have close to 40k in it.

User Image NEWBIGTECH Posted - 1 week ago

$ATHE

User Image tlaw6000 Posted - 1 week ago

$ATHE slowly adding till january

User Image CARTE_BLANCHE_DEVEREAUX Posted - 1 week ago

$ATHE $IBRX $SLS It is weird to look at a stock at 7:00 a.m. PST and see that I'm the only person buying it... like... THE ONLY PERSON. Apparently my stupidity in BIOS has no limit.

User Image tlaw88999 Posted - 2 weeks ago

$ATHE too quiet....but im joining the party....been watching this a while..time to get in/gl all

User Image pawbar Posted - 2 weeks ago

$ATHE isn't this a 10-bagger, assuming the phase 2 results in January will be statistically significant?

User Image MomentumWhale Posted - 2 weeks ago

$XYLO One of the smallest floats on the Nasdaq is getting found! Could squeeze 300% like $FOXO and $ATHE and $ZCAR did recently.. XYLO starting its move up now

User Image glanvill Posted - 2 weeks ago

$ATHE Does anyone have access to this? https://academic.oup.com/metallomics/article-abstract/16/10/mfae044/7774404?redirectedFrom=fulltext

User Image BioTuesdays Posted - 2 weeks ago

Alterity Therapeutics has highlighted a peer-reviewed article published in Metallomics, emphasizing the significance of iron and iron-targeting agents, such as the company’s ATH434, in treating neurodegenerative diseases $ATHE https://biotuesdays.com/2024/11/06/alterity-underscores-published-data-on-role-of-iron-in-neurodegenerative-diseases/

User Image Cub911 Posted - 2 weeks ago

$ATHE

User Image GuineaPigForever Posted - 2 weeks ago

$ATHE took profits from bnox. Brought them here. Have had this on watch for a while now. Always believed in it.

User Image PatrickBateman69 Posted - 2 weeks ago

$ATHE in at 1,18, Lets get some volume!

User Image PatrickBateman69 Posted - 2 weeks ago

$ATHE Buying some extra shares tomorrow. Pretty decent pipeline, they just lack the cash. It’s always a risky play with biotech, but seems like a good time to enter in terms of the low share price.

User Image E63AMGs Posted - 2 weeks ago

@MS_Tammy What do you think about $BLMZ BloomZ? The chart seems to be set up for a nice move up. Company is taking on new clients and projects. $EZGO $TOVX $BURU $ATHE

User Image Weatherman118 Posted - 2 weeks ago

$VSTE smashed it with the team for +100% gains from today's live entry alert! 🔥🤑💰🎯 3.70 entries ran to 8.00! See timestamps and guidance! Don't miss the next one! Full guidance in our room! Step by step! Stop missing out on early entries & guidance! If you want to be a succesful day trader. Come and elevate your trading game today & learn to be profitable in the stockmarkets! Join the community for instant push notifications and guidance to be profitable in the stockmarket! Link in bio $ATHE $GSAT $CDXC $GRI

User Image Weatherman118 Posted - 2 weeks ago

Bang bang! Massive winner to end this slow session! $VSTE 3.70 entries hit 8.00! for +110% gains from entry! Nailed all the levels!🤑🔥🎯 See timestamps before and after! Stop missing out on early entries & guidance! If you want to be a succesful day trader. Come and elevate your trading game today & learn to be profitable in the stockmarkets! Join the community for instant push notifications and guidance to be profitable in the stockmarket! Link in bio $ATHE $GSAT $HOLO $ESNC on watch!

User Image Profitrip Posted - 2 weeks ago

$ATHE > . 55> / gap on daily over .70 / 38M float

Analyst Ratings
Benchmark Speculative Buy Mar 7, 24
Ladenburg Thalmann Buy Jun 5, 23